Q2 2026 saw 14% revenue growth and 38% EPS growth year-over-year, with strong performance in both MedTech & Specialty Audio and Precision Devices segments. Robust bookings, a healthy backlog, and favorable pricing support a raised full-year outlook of 10%-12% revenue growth and 20%-24% adjusted EBITDA growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.